Medical

As medicine continues to advance, there are many good drugs and options to fight cancer. Just recently, a study showed that the NALIRIFOX regimen significantly improved the overall survival of patients with advanced pancreatic ductal adenocarcinoma who had not received previous treatment.

Many patients with diabetes are painless when their blood sugar is high, and retinopathy is also silent and imperceptible. Therefore, the majority of diabetes patients should be reminded that after the diagnosis of diabetes, they must regularly screen the sugar network, and early diagnosis and treatment is the key. Early detection, early treatment and regular reexamination can avoid more than 90% of severe visual impairment.

A three-drug combination regimen significantly prolongs survival in patients with HPV-positive cancers, new data from a clinical trial shows. For patients who had not been treated with immune checkpoint inhibitors, it resulted in significant tumour shrinkage in 88% of patients, and even in patients who failed immune checkpoint inhibitor treatment, 63% had significant tumour shrinkage.

In today's rapidly changing world of science and technology, a research result that sounds very sci-fi will appear from time to time. No, a paper published in the journal Science Robotics belongs to this scope: a cell regeneration robot that successfully works in vivo.

Who is CinCor?

Afamitresgene Autoleucel, also known as Afami-cel or ADP-A2M4, is a novel TCR-T cell immunotherapy that has produced durable and promising results in patients with advanced synovial sarcoma or mucinous/round cell liposarcoma

Pfizer's new treatment, Elranatamab, has received Breakthrough Therapy designation from the FDA for the treatment of patients with relapsed or refractory multiple myeloma. Data from the trial showed a patient efficacy rate of 61.0% and that once the therapy is effective, efficacy is maintained for more than six months in over 90% of patients!

The FDA has recently granted orphan drug designation to Ezurpimtrostat, a PPT-1 inhibitor for the treatment of patients with hepatocellular carcinoma (HCC).

In recommendations released on 2 February 2023, the National Comprehensive Cancer Network (NCCN) recommends that doctors consider neratinib for patients with HER2-negative metastatic breast cancer, regardless of their estrogen receptor status.

The US FDA has approved Elacestrant, the first oral selective estrogen receptor degrader (SERD), for the treatment of patients with advanced or metastatic breast cancer who are estrogen receptor positive, HER2 negative and have an ESR1 mutation. Results of the trial showed that patients treated with Elacestrant had a 45% reduction in the risk of disease progression or death.